Halia Therapeutics presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit. Dr. David J. Bearss, President, and CEO of Halia Therapeutics, highlighted results demonstrating how using an allosteric targeting approach to a component of the NLRP3 complex enabled the design of a new class of compounds that target…
eTurboNews amanqaku ngababhalisi kuphela. Umrhumo ngu fREE.
Ababhalisi bangena apha Cofa apha ukuze ubhalise FREE
Ababhalisi bangena apha Cofa apha ukuze ubhalise FREE
INTO ONOKUYITHATHA KWELI NQAKU:
- Bearss, President, and CEO of Halia Therapeutics, highlighted results demonstrating how using an allosteric targeting approach to a component of the NLRP3 complex enabled the design of a new class of compounds that target….
- I-Halia Therapeutics ibonise idatha namhlanje kwinkqubo yayo ye-NLRP3 inhibitor kwiNgqungquthela yoNyaka ye-10 ye-Neurodeergenerative Drug Development Summit.
- Dr.
